Methods of treating pain using an IL-31Ra or OSMR-b antagonist

• US 8,974,783 B2
• Filed: 02/07/2014
• Issued: 03/10/2015
• Est. Priority Date: 01/10/2006
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Yao, Yue, Bilsborough, Janine
• Primary Examiner(s): Saoud, Christine J
• Assistant Examiner(s): LOCKARD, JON MCCLELLAND
• Application Number:
  US14/175,117
• Publication Number:
  US 20140186346A1
• Time in Patent Office: 396 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/1793 for cytokines; for lymphokines; for interferons
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Claims

1. A method of treating pain in a subject in need thereof comprising administering to the subject a monoclonal antibody or antigen-binding fragment thereof that specifically binds to a first receptor consisting of amino acid residues 1-662 of SEQ ID NO:

8, or a second receptor consisting of amino acid residues 1-979 of SEQ ID NO;

16, or a heterodimeric receptor comprising the first and second receptors, wherein the pain is associated with a burn, neuropathy or allodynia, and wherein after administration the pain is reduced.

2. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment is humanized.

3. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment is human.

4. The method of claim 1, wherein the isotype of the monoclonal antibody is IgG.

5. The method of claim 4, wherein the isotype of the monoclonal antibody is IgG1, IgG2, IgG3 or IgG4.

6. The method of claim 1, wherein the antigen-binding fragment is a Fab, Fab′

, F(ab′

)₂ or scFv.

7. The method of claim 6, wherein the antigen-binding fragment further comprises a human immunoglobulin constant region.